Clin2
NCT07684144Possibly a fitRecruiting

Long-term study of a weight-loss medication for people who completed an earlier trial

ObesityOverweightDiabetes Mellitus, Type 2

Treatments studied

Part of Hormones & metabolism clinical trials.

This study tests the long-term effects of a medication called maridebart cafraglutide for weight management. It is for people who already completed a 72-week study of this drug and want to continue treatment.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
950 people
Ages
18 years to 99 years
Study type
Interventional

Who can take part

  • You must have completed the 72-week visit in the original MARITIME-2 study.
  • You must not have stopped taking the study drug early in the previous trial.
  • You must be willing to use birth control while on the drug and for 16 weeks after your last dose.
  • You cannot have had surgery or a device placed for weight loss planned during this study.
  • You must not be pregnant, breastfeeding, or planning to become pregnant during the study.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07684235Recruiting· Phase 3
Long-term study of a weight-loss drug for trial graduates

This study tests a drug called Maridebart Cafraglutide for long-term weight management in people who completed a previous related trial. It looks at how well the drug works and its safety over time.

Anniston, Alabama
NCT07037459Recruiting· Phase 3
A study of a new drug for heart failure with obesity

This trial tests a medication called maridebart cafraglutide for people with heart failure (where the heart doesn't pump as well as it should) and obesity. The goal is to see if it can help improve symptoms and outcomes.

Birmingham, Alabama
NCT07037433Recruiting· Phase 3
Heart protection study for people with heart disease and overweight

This study tests a new weekly injection (maridebart cafraglutide) to see if it helps lower the risk of heart problems in people with heart disease and overweight. It is for adults who have had a heart attack, stroke, or artery blockages and also have a BMI of 27 or higher.

Daphne, Alabama
NCT07225686Recruiting· Phase 3
Maridebart Cafraglutide for sleep apnea in adults on CPAP

This study is testing whether a new medicine, called Maridebart Cafraglutide, can help people with obstructive sleep apnea who are already using a CPAP machine. The medicine may help with weight loss and potentially improve sleep apnea. Participants will either receive the medicine or a placebo (an inactive substance), and the study lasts for several months.

Northridge, California
NCT07767175Not yet recruiting· Phase 1
Weight loss study for adults with overweight or obesity

This study tests an investigational medication, called NNC0721-8060, to see how it works in people with excess weight (overweight or obesity). It may help with weight loss, but is still in early human testing.

Lenexa, Kansas
NCT07793019Not yet recruiting· Phase 1
Weight loss and safety study in overweight adults

This trial tests an experimental medication that may help with weight loss. It aims to see how safe the drug is and how the body responds, possibly leading to a new treatment option for obesity.

Beijing, Beijing Municipality

Hear when a new Obesity trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.